The intracutaneous reactivity test is a core component of the biological evaluation program for medical devices, designed to assess the localized irritation potential of device extracts after intradermal injection into rabbit tissue. Performed in accordance with ISO 10993-10 (and its Chinese counterpart GB/T 16886.10), this test is routinely required for regulatory submissions where devices contact breached skin, mucosal surfaces, or internal tissues. This article provides a comprehensive technical overview of the test principle, sample preparation, methodology, scoring criteria, and its role in global market approval.
Technical Overview
The intracutaneous (intradermal) reactivity test is an in vivo screening assay used to evaluate whether extracts from a medical device or biomaterial provoke localized irritation when injected into the skin. It forms part of the biological evaluation framework defined by ISO 10993-1 (Evaluation and testing within a risk management process), with the specific test method described in ISO 10993-10, Biological evaluation of medical devices — Part 10: Tests for irritation and skin sensitization. Sample extraction and preparation follow ISO 10993-12, while the harmonized Chinese national standard GB/T 16886.10 describes an equivalent procedure for submissions to the NMPA.
The principle of the test is straightforward: device extracts are prepared using both a polar vehicle (typically 0.9% sodium chloride solution) and a non-polar vehicle (typically a vegetable oil such as cottonseed or sesame oil). Small volumes of each extract are then injected intradermally into the clipped backs of healthy albino rabbits, alongside injections of the corresponding blank extraction vehicles as negative controls. The injection sites are examined macroscopically at defined time points, and the tissue response—specifically erythema (redness), eschar formation, and edema (swelling)—is graded against a standardized scoring scale. The test is particularly valuable for devices whose final use involves contact with living tissue that cannot be adequately evaluated using surface skin-patch approaches.
Testing Samples
Finished Medical Devices with Internal or Breached-Skin Contact
Typical test articles include devices in their final, sterilized, and ready-to-use condition, such as intravenous and urinary catheters, infusion sets and administration tubing, syringes and cannulae, hemodialysis circuits and blood oxygenators, endotracheal tubes, wound dressings intended for breached skin, surgical drapes and adhesives, orthopedic and dental implants, sutures, and sealants. Testing the finished device ensures that all processing aids, sterilization residues, packaging interactions, and extractable additives are captured in the assessment.
Polymeric, Metallic, and Elastomeric Materials
During design and development, candidate materials—silicones, polyurethanes, PVC compounds, latex and synthetic elastomers, biocompatible metal alloys, coatings, adhesives, printing inks, and masterbatch formulations—are frequently screened before device-level testing is performed. Material coupons representative of the final processing route (including molding, extrusion, curing, and sterilization) are extracted and evaluated to support material selection decisions.
Sample Preparation Considerations
Samples are prepared under aseptic conditions and extracted according to ISO 10993-12. For devices with defined surface geometry, the standard surface-area-to-volume ratio is 6 cm² per milliliter of extraction vehicle. For irregularly shaped or porous solids, a mass-based ratio of approximately 0.2 g per milliliter is applied, with justified deviations documented. If a device consists of multiple components with different material chemistries, the laboratory may perform separate extractions to preserve the ability to attribute any reaction to its source.
Testing Items
The testing items evaluated in the intracutaneous reactivity test include:
- Intracutaneous irritation potential of the polar extract versus the polar vehicle control
- Intracutaneous irritation potential of the non-polar extract versus the non-polar vehicle control
- Erythema and eschar formation at each injection site, graded on a 0 to 4 scale
- Edema formation at each injection site, graded on a 0 to 4 scale
- Occurrence of any secondary tissue reactions, such as necrosis, blistering, or hemorrhage, which are recorded and reported
Testing Methods
Extraction Procedure
Extraction is performed simultaneously on the test sample and on blank vehicles using one of the standard condition sets from ISO 10993-12: 37 °C for 24 ± 2 hours, 50 °C for 72 ± 2 hours, 70 °C for 24 ± 2 hours, or 121 °C for 1 hour. The 37 °C / 24-hour condition is the most common default because it simulates physiological use conditions. Extracts are inspected before use; any discoloration, turbidity, or particulate formation is documented, since a highly acidic or alkaline extract can produce non-specific physical irritation and confound interpretation.
Animal Test Design
The study is conducted in healthy adult albino rabbits (commonly two to three animals, per the current edition of ISO 10993-10) that have been acclimatized and confirmed free of pre-existing skin conditions. The dorsal area is clipped free of fur, and a grid of injection sites is established. At each site, 0.2 mL of the test extract or the corresponding blank vehicle is injected intradermally using a fine-gauge needle. A typical configuration places five replicate sites for the polar extract and five for the non-polar extract on one side of each animal, with the matching blank vehicle controls injected at five sites on the contralateral side. Site allocation is randomized to minimize positional bias.
Observation and Scoring
Injection sites are examined macroscopically at approximately 24, 48, and 72 hours after injection (with an additional immediate observation in some protocols). Each site is scored for erythema/eschar and edema using the ISO 10993-10 grading scale:
- Erythema and eschar: 0 = no erythema; 1 = very slight erythema, barely perceptible; 2 = well-defined erythema; 3 = moderate to severe erythema; 4 = severe erythema (beet redness) to slight eschar formation
- Edema: 0 = no edema; 1 = very slight edema, barely perceptible; 2 = well-defined edema with raised edges; 3 = moderate edema, raised approximately 1 mm; 4 = severe edema, raised more than 1 mm and extending beyond the exposure area
Evaluation Criteria
For each animal, the erythema and edema scores are summed across all observation time points and averaged for the test sites and the corresponding control sites. The device meets the requirements of the test if the difference between the mean score of the test extract sites and that of the blank vehicle control sites does not exceed 1.0, indicating no evidence of intracutaneous irritation attributable to the device. If the test response exceeds the control, the study director may order a confirmatory repeat, a chemical characterization of the extract, or a toxicological risk assessment to identify the causative leachable. All work is typically conducted in accredited third-party laboratories under Good Laboratory Practice principles consistent with OECD guidelines, with animal use reviewed and approved by the institutional ethics committee and designed in accordance with the 3Rs (replacement, reduction, refinement).
Applications
Intracutaneous reactivity data supports a wide range of regulatory and engineering objectives, including:
- Regulatory registration submissions for device market authorization in China, the United States, the European Union, and other jurisdictions, where the test is included in the ISO 10993-1 biological evaluation test plan
- Biological evaluation of surface devices contacting breached or compromised skin, external communicating devices (tissue/bone/dentin contact, blood path indirect, circulating blood), and implantable devices
- Material screening and comparative selection during research and development, allowing early elimination of irritant formulations
- Change control and vendor qualification, verifying that modifications to resin suppliers, processing parameters, coatings, sterilization methods, or packaging do not introduce new irritant hazards
- Support of technical documentation under quality management systems and risk management files aligned with ISO 14971
FAQ
What is the intracutaneous reactivity test?
It is an in vivo biological evaluation assay in which polar and non-polar extracts of a medical device are injected into the skin of rabbits to determine whether the device releases substances capable of causing localized tissue irritation. Responses are graded for erythema, eschar, and edema and compared with blank vehicle controls.
Which standards govern this test?
The primary standard is ISO 10993-10 for irritation and skin sensitization testing, supported by ISO 10993-12 for sample preparation and ISO 10993-1 for the overall evaluation strategy. The Chinese national standard GB/T 16886.10 and GB/T 16886.12 series are harmonized equivalents accepted for NMPA submissions, and ASTM F749 also describes a related intracutaneous injection practice.
When is intracutaneous testing required?
The test is generally expected for devices that contact living tissue below intact skin—such as catheters, infusion components, surgical instruments used in tissue contact, and implants—or that contact breached skin and mucous membranes. It may be omitted only when a documented gap analysis, chemical characterization, and toxicological risk assessment provide a strong scientific justification, which regulators review case by case.
What are the extraction vehicles and conditions?
The standard vehicles are 0.9% sodium chloride injection (polar) and vegetable oil such as cottonseed or sesame oil (non-polar); additional vehicles such as ethanol/water or polyethylene glycol 400/water mixtures may be used when justified. Extraction is performed at conditions such as 37 °C for 24 hours, 50 °C for 72 hours, 70 °C for 24 hours, or 121 °C for 1 hour, selected to be aggressive yet not degrade the material in a way that misrepresents clinical exposure.
What is the pass criterion?
The device passes if the mean irritation score (erythema plus edema, summed over all observation periods) of the test extract sites does not exceed the corresponding blank vehicle control by more than 1.0. A result within this margin is reported as no evidence of intracutaneous irritation.
How many animals are used, and how long does the test take?
The current edition of ISO 10993-10 specifies a small number of rabbits, typically two to three, each receiving replicate injections of both extracts and both controls. Including acclimatization, extraction, injection, the 72-hour observation period, and reporting, a standard study is usually completed within two to four weeks, subject to laboratory scheduling.
Can in vitro methods replace the intracutaneous test?
In vitro skin irritation models reconstructed from human epidermis are now accepted for dermal irritation endpoints under ISO 10993-23 and can reduce or replace rabbit skin patch testing for surface-contacting devices. However, there is no fully validated in vitro replacement for the intracutaneous route, so the rabbit intradermal test remains the recognized method for tissue-contact and implant-contact scenarios.
What can invalidate the test or produce misleading results?
Common confounders include extracts with extreme pH or osmolality, particulate contamination, accidental subcutaneous rather than intradermal injection, pre-existing skin lesions on the animals, or improper storage of extracts before dosing. A well-designed study includes control of these variables, documentation of injection technique verification, and repeat provisions in the study plan.
Summary
The intracutaneous reactivity test remains one of the most frequently performed assays in medical device biological evaluation because it is sensitive, rapid, well standardized, and directly relevant to tissue-contacting applications. Manufacturers should ensure that test articles represent the final product in its sterilized, ready-to-use state, that extraction is justified per ISO 10993-12, and that studies are executed in accredited third-party laboratories with experienced study directors. A well-documented intracutaneous reactivity report, integrated into a risk-based ISO 10993-1 evaluation file, materially strengthens regulatory submissions and helps bring safer devices to patients worldwide.